Health Catalyst (HCAT)
NASDAQ:HCAT
Want to see HCAT full AI Analyst Report?
HCAT Stock Chart & Stats
$1.32
$0.34(4.94%)
At close: 4:00 PM EST
$1.32
$0.34(4.94%)
Day’s Range― - ―
52-Week Range$0.96 - $4.13
Previous CloseN/A
Volume315.36K
Average Volume (3M)628.93K
Market Cap
$130.05M
Enterprise Value$241.51M
Total Cash (Recent Filing)$108.82M
Total Debt (Recent Filing)$170.58M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 12, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding73,894,020
10 Day Avg. Volume592,331
30 Day Avg. Volume628,929
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.54
P/FCF Ratio-704.86
Enterprise Value/Market Cap1.86
Enterprise Value/Revenue0.80
Enterprise Value/Gross Profit1.74
Enterprise Value/Ebitda-1.26
Forecast
1Y Price Target
$2.11Price Target Upside59.63% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)0.04
Revenue Forecast (FY)$263.04M
Bulls Say, Bears Say
Bulls Say
Balance-sheet De-leveraging Via Vitalware SaleA planned $147M divestiture earmarked to repay the ~$160M term loan meaningfully de-risks leverage. Lower debt reduces interest burden and covenant risk, improves financial flexibility to fund product investments and migrations, and supports multi-quarter execution of strategy.
Positive Cash Generation And LiquidityReturn to positive operating and free cash flow and a cash balance near $109M provide durable runway to absorb migration costs and fund Project NEXUS savings. Stronger cash generation lowers refinancing risk and gives management flexibility to prioritize high-return product development over short-term financing concerns.
Technology Margin Expansion & AI Product MomentumHigher-margin, cloud-native analytics and an AI strategy anchored in long-standing proprietary clinical improvement data support durable margin expansion as adoption shifts from services to subscriptions. Sustained product-led adoption and engineering productivity gains can lift recurring revenue quality over multiple quarters.
Bears Say
Migration-driven Churn And At-risk ARRThe Ignite migration has created structural churn risk: losing or downselling material ARR reduces recurring revenue visibility for several quarters. Even a partial loss materially compresses near-term revenue and raises execution risk as the company must both stabilize existing customers and convert bookings into durable subscription revenue.
Stagnant To Declining Revenue TrendNegative TTM revenue growth signals weakening demand or transitional disruption from product migration. Over a multi-month horizon this limits operating leverage, constrains reinvestment capacity, and makes margin improvement dependent on cost cuts rather than organic growth — a less durable path to profitability.
Structural Unprofitability And Wide Net LossA very large accounting loss and extremely negative net margin indicate the business still lacks sustained operating profitability. Such structural losses can erode equity value and require consistent cash generation or repeated cost actions to sustain operations, raising execution and capital-allocation risk over the medium term.
Health Catalyst News
HCAT FAQ
What was Health Catalyst’s price range in the past 12 months?
Health Catalyst lowest stock price was $0.95 and its highest was $4.13 in the past 12 months.
What is Health Catalyst’s market cap?
Health Catalyst’s market cap is $130.05M.
When is Health Catalyst’s upcoming earnings report date?
Health Catalyst’s upcoming earnings report date is Aug 12, 2026 which is in 47 days.
How were Health Catalyst’s earnings last quarter?
Health Catalyst released its earnings results on May 11, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of $0.011 by $0.009.
Is Health Catalyst overvalued?
According to Wall Street analysts Health Catalyst’s price is currently Undervalued.
Does Health Catalyst pay dividends?
Health Catalyst does not currently pay dividends.
What is Health Catalyst’s EPS estimate?
Health Catalyst’s EPS estimate is 0.03.
How many shares outstanding does Health Catalyst have?
Health Catalyst has 73,894,020 shares outstanding.
What happened to Health Catalyst’s price movement after its last earnings report?
Health Catalyst reported an EPS of $0.02 in its last earnings report, beating expectations of $0.011. Following the earnings report the stock price went up 7.246%.
Which hedge fund is a major shareholder of Health Catalyst?
Currently, no hedge funds are holding shares in HCAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Health Catalyst Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.11 (59.63% Upside)
$2.11 (59.63% Upside)
Blogger Sentiment
Bullish
HCAT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 793.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
-99.78%
Trailing 12-Months
Asset Growth
-53.77%
Trailing 12-Months
Company Description
Health Catalyst
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.
HCAT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and financial progress with meaningful near-term headwinds. Positives include a revenue beat, improved adjusted gross margin, a sizable adjusted EBITDA beat, strong cash generation, a detailed restructuring program (Project NEXUS) targeting ~$30M of annualized savings, early product and AI traction, and reinstated full-year guidance. Negatives center on migration-driven churn (~$30M at-risk ARR with an expected ~$20M 2026 impact), transitional duplicate hosting and data-loading costs weighing on margins, expected professional services margin decline, and near-term restructuring charges and execution risk. Overall, management laid out a coherent plan to address issues and improve long-term durability but acknowledged short-term revenue and margin pressure tied to migration and transformation.View all HCAT earnings summariesHCAT Stock 12 Month Forecast
Average Price Target
$2.11
▲(59.63% Upside)
Technical Analysis
HealthStream
―
OptimizeRx
―
Evolent Health
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
7.81% Insiders
13.40% Mutual Funds
53.01% Other Institutional Investors
15.46% Public Companies and
Individual Investors